Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive the group has formed a new licensing deal with a German pharma company to commercialize treosulfan in the US.
d’Entremont says the drug is developed for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. This now grants Medexus’ US subsidiary Medexus Pharma Inc the exclusive license to commercialize the drug.